Shares of Cosmo Pharmaceuticals N.V. (COPN.SW,CMOPF) were losing around 14 percent in the morning trading in Switzerland after the healthcare company reported a loss in its fiscal 2025, compared to prior year's profit, amid sharply lower revenues.
In fiscal 2025, loss attributable to owners of the company was 3.61 million euros, compared to prior year's profit of 133.24 million euros.
Loss per share was 0.226 euro, compared to profit of 8.115 euros last year.
Operating loss was 3.24 million euros, compared to prior year's profit of 148.88 million euros.
Revenue declined to 104.17 million euros from 266.79 million euros last year.
In Switzerland, Cosmo shares were trading at 92.60 Swiss francs, down 13.78 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.